{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:21:40Z","timestamp":1769854900737,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Three randomised controlled trials (RCTs) have demonstrated that first-line cryoballoon pulmonary vein isolation decreases atrial tachycardia in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drugs (AADs). The aim of this study was to develop a cost-effectiveness model (CEM) for first-line cryoablation compared with first-line AADs for the treatment of PAF. The model used a Danish healthcare perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Individual patient-level data from the Cryo-FIRST, STOP AF and EARLY-AF RCTs were used to parameterise the CEM. The model structure consisted of a hybrid decision tree (one-year time horizon) and a Markov model (40-year time horizon, with a three-month cycle length). Health-related quality of life was expressed in quality-adjusted life years (QALYs). Costs and benefits were discounted at 3% per year. Model outcomes were produced using probabilistic sensitivity analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>First-line cryoablation is dominant, meaning it results in lower costs (-\u20ac2,663) and more QALYs (0.18) when compared to first-line AADs. First-line cryoablation also has a 99.96% probability of being cost-effective, at a cost-effectiveness threshold of \u20ac23,200 per QALY gained. Regardless of initial treatment, patients were expected to receive\u2009\u223c\u20091.2 ablation procedures over a lifetime horizon.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>First-line cryoablation is both more effective and less costly (i.e. dominant), when compared with AADs for patients with symptomatic PAF in a Danish healthcare system.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-024-04024-5","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T08:01:44Z","timestamp":1721116904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A danish healthcare-focused economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation"],"prefix":"10.1186","volume":"24","author":[{"given":"Morten Lock","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe W. E.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"T\u00f8nnesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette Lundsby","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Kuniss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Ismyrloglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oussama","family":"Wazni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Mealing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Sale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Bromilow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Battista","family":"Chierchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"issue":"2","key":"4024_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217\u201321.","journal-title":"Int J Stroke"},{"issue":"7","key":"4024_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/pace.13356","volume":"41","author":"MM Streur","year":"2018","unstructured":"Streur MM, Ratcliffe SJ, Callans DJ, Shoemaker MB, Riegel BJ. Atrial fibrillation symptom profiles associated with healthcare utilization: a latent class regression analysis. Pacing Clin Electrophysiol. 2018;41(7):741\u201349.","journal-title":"Pacing Clin Electrophysiol"},{"key":"4024_CR3","doi-asserted-by":"crossref","unstructured":"Crandall MA, Bradley DJ, Packer DL, Asirvatham SJ. Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies. Mayo Clinic Proceedings. 2009;84(7):643\u2009\u2013\u200962.","DOI":"10.1016\/S0025-6196(11)60754-4"},{"key":"4024_CR4","doi-asserted-by":"crossref","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2020;42(5):373\u2013498.","DOI":"10.1093\/eurheartj\/ehab648"},{"key":"4024_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/CLEP.S374468","volume":"14","author":"ER Hegelund","year":"2022","unstructured":"Hegelund ER, Kjerpeseth LJ, Mortensen LH, Igland J, Berge T, Anjum M, et al. Prevalence and incidence rates of Atrial Fibrillation in Denmark 2004\u20132018. Clin Epidemiol. 2022;14:1193\u2013204.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"4024_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s12913-017-2652-y","volume":"17","author":"SP Johnsen","year":"2017","unstructured":"Johnsen SP, Dalby LW, T\u00e4ckstr\u00f6m T, Olsen J, Fraschke A. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res. 2017;17(1):714.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"4024_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2029980","volume":"384","author":"JG Andrade","year":"2021","unstructured":"Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or Drug Therapy for initial treatment of Atrial Fibrillation. N Engl J Med. 2021;384(4):305\u201315.","journal-title":"N Engl J Med"},{"issue":"7","key":"4024_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/europace\/euab029","volume":"23","author":"M Kuniss","year":"2021","unstructured":"Kuniss M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace. 2021;23(7):1033\u201341.","journal-title":"Europace"},{"issue":"4","key":"4024_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2029554","volume":"384","author":"OM Wazni","year":"2021","unstructured":"Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ablation as initial therapy for Atrial Fibrillation. N Engl J Med. 2021;384(4):316\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"4024_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2212540","volume":"388","author":"JG Andrade","year":"2023","unstructured":"Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, et al. Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. N Engl J Med. 2023;388(2):105\u201316.","journal-title":"N Engl J Med"},{"key":"4024_CR11","doi-asserted-by":"crossref","unstructured":"Andrade JG, Moss JWE, Kuniss M, Sadri H, Wazni DO, Sale A, et al. The cost-effectiveness of First-Line Cryoablation versus First-Line Antiarrhythmic drugs in Canadian patients with Paroxysmal Atrial Fibrillation. Canadian Journal of Cardiology; 2023.","DOI":"10.1016\/j.cjca.2023.11.019"},{"issue":"1","key":"4024_CR12","doi-asserted-by":"publisher","first-page":"e002423","DOI":"10.1136\/openhrt-2023-002423","volume":"11","author":"J Paisey","year":"2024","unstructured":"Paisey J, Moss J, Andrade J, Kuniss M, Wazni O, Chierchia GB, et al. Economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English National Health Service perspective. Open Heart. 2024;11(1):e002423.","journal-title":"Open Heart"},{"issue":"9","key":"4024_CR13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.hroo.2023.07.007","volume":"4","author":"O Wazni","year":"2023","unstructured":"Wazni O, Moss J, Kuniss M, Andrade J, Chierchia GB, Mealing S, et al. An economic evaluation of first-line cryoballoon ablation vs antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a U.S. Medicare perspective. Heart Rhythm O2. 2023;4(9):528\u201337.","journal-title":"Heart Rhythm O2"},{"key":"4024_CR14","unstructured":"Finansministeriet. Dokumentationsnotat \u2013 den samfunds\u00f8konomiske diskonteringsrente. 2021. https:\/\/fm.dk\/media\/18371\/dokumentationsnotat-for-den-samfundsoekonomiske-diskonteringsrente_7-januar-2021.pdf."},{"key":"4024_CR15","unstructured":"Styrelsen S-IDRG. 2023. https:\/\/casemix360.solutions.iqvia.com\/InteractiveProd#\/."},{"key":"4024_CR16","unstructured":"Sundhedsdata. Sygdomsbyrden i Danmark\u2014 sygdommeInteraktivDRG. 2022. https:\/\/casemix360.solutions.iqvia.com\/InteractiveProd#\/."},{"key":"4024_CR17","unstructured":"NHS England. National Schedule of NHS costs 2021\/22. In; 2023."},{"key":"4024_CR18","unstructured":"Marie Jakobsen EK, Fredslund, Christophe Kolodziejczyk. Omkostninger ved blodprop i hjernen og bl\u00f8dninger blandt patienter med atrieflimren i Danmark. En registerbaseret \u2019cost of illness\u2019-analyse: 2014. https:\/\/www.vive.dk\/da\/udgivelser\/omkostninger-ved-blodprop-i-hjernen-og-bloedninger-blandt-patienter-med-atrieflimren-i-danmark-4z6go3xq\/."},{"issue":"12","key":"4024_CR19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/ejhf.1577","volume":"21","author":"JS Bundgaard","year":"2019","unstructured":"Bundgaard JS, Mogensen UM, Christensen S, Ploug U, R\u00f8rth R, Ibsen R, et al. The economic burden of heart failure in Denmark from 1998 to 2016. Eur J Heart Fail. 2019;21(12):1526\u201331.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"4024_CR20","doi-asserted-by":"publisher","first-page":"e0226730","DOI":"10.1371\/journal.pone.0226730","volume":"14","author":"F Witassek","year":"2019","unstructured":"Witassek F, Springer A, Adam L, Aeschbacher S, Beer JH, Blum S, et al. Health-related quality of life in patients with atrial fibrillation: the role of symptoms, comorbidities, and the type of atrial fibrillation. PLoS ONE. 2019;14(12):e0226730.","journal-title":"PLoS ONE"},{"issue":"2","key":"4024_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/cer-2020-0224","volume":"10","author":"LM Sawyer","year":"2021","unstructured":"Sawyer LM, Witte KK, Reynolds MR, Mittal S, Grimsey Jones FW, Rosemas SC, et al. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. J Comp Eff Res. 2021;10(2):127\u201341.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"4024_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","volume":"12","author":"A G\u00f6hler","year":"2009","unstructured":"G\u00f6hler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, et al. Utility estimates for decision\u2013Analytic modeling in Chronic Heart failure\u2014health states based on New York Heart Association Classes and Number of Rehospitalizations. Value Health. 2009;12(1):185\u201387.","journal-title":"Value Health"},{"key":"4024_CR23","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2022. https:\/\/www.R-project.org."},{"issue":"5","key":"4024_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B Van Hout","year":"2012","unstructured":"Van Hout B, Janssen M, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"issue":"10","key":"4024_CR25","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","volume":"14","author":"H Calkins","year":"2017","unstructured":"Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275\u2013444.","journal-title":"Heart Rhythm"},{"key":"4024_CR26","unstructured":"XE. Trusted Global Currency Converter & Money Transfer Solutions. 2023. https:\/\/www.xe.com\/."},{"key":"4024_CR27","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J. Self-Reported Population Health: An International Perspective based on EQ-5D. 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"4024_CR28","unstructured":"Statistics Denmark. https:\/\/www.dst.dk\/en\/Statistik\/emner\/priser-og-forbrug\/forbrugerpriser."},{"key":"4024_CR29","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual 2022."},{"key":"4024_CR30","doi-asserted-by":"crossref","unstructured":"Frausing M, Johansen JB, Afonso D, J\u00f8rgensen OD, Olsen T, Gerdes C et al. Cost-effectiveness of an antibacterial envelope for infection prevention in patients undergoing cardiac resynchronization therapy reoperations in Denmark. Europace. 2023;25(6).","DOI":"10.1093\/europace\/euad159"},{"issue":"34","key":"4024_CR31","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta12340","volume":"12","author":"M Rodgers","year":"2008","unstructured":"Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess. 2008;12(34):iii\u2013ivxi.","journal-title":"Health Technol Assess"},{"key":"4024_CR32","unstructured":"National Institute for Health and Care Excellence. NICE guideline NG196: Cost-effectiveness analysis J3: Ablation. 2021. https:\/\/www.nice.org.uk\/guidance\/ng196\/evidence\/j3-ablation-costeffectiveness-analysis-pdf-326949243734."},{"issue":"2","key":"4024_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/jce.15317","volume":"33","author":"LWM Leung","year":"2022","unstructured":"Leung LWM, Imhoff RJ, Marshall HJ, Frame D, Mallow PJ, Goldstein L, et al. Cost-effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom. J Cardiovasc Electrophysiol. 2022;33(2):164\u201375.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"7","key":"4024_CR34","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.amjmed.2021.01.017","volume":"134","author":"H Gibbs","year":"2021","unstructured":"Gibbs H, Freedman B, Rosenqvist M, Virdone S, Mahmeed WA, Ambrosio G, et al. Clinical outcomes in asymptomatic and symptomatic Atrial Fibrillation presentations in GARFIELD-AF: implications for AF Screening. Am J Med. 2021;134(7):893\u2013e90111.","journal-title":"Am J Med"},{"key":"4024_CR35","doi-asserted-by":"crossref","unstructured":"Sgreccia D, Manicardi M, Malavasi VL, Vitolo M, Valenti AC, Proietti M et al. Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and Meta-analysis of 81,462 patients. J Clin Med. 2021;10(17).","DOI":"10.3390\/jcm10173979"},{"key":"4024_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijcard.2015.05.011","volume":"191","author":"Q Xiong","year":"2015","unstructured":"Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: a systematic review of age\/gender differences and cardiovascular outcomes. Int J Cardiol. 2015;191:172\u20137.","journal-title":"Int J Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04024-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T08:03:44Z","timestamp":1721117024000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04024-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4024"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04024-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Studies were approved by the below ethics committees (EE) or institutional review boards (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MLK reports research funding from Medtronic and Biosense-Webster. DA, JM, SM, TB, EL, DL report being employees of a consultancy company and to have undertaken the work in this manuscript as part of a wider consulting agreement. MDR reports funding from Medtronic and Biosense-Webster. MLJ, EI, AS report being employees and stockholders of Medtronic. MK reports honoraria for teaching, participation in clinical trials, proctoring and lectures\/presentations from Medtronic. JA reports grants and personal fees from Medtronic, grants from Baylis, personal fees from Biosense-Webster. OW reports grants from Medtronic and personal fees from Biosense Webster and Boston Scientific. GBC reports compensation for teaching purposes and proctoring from Medtronic, Abbott, Biotronik, Boston Scientific, and Acutus Medical.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}